Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia

Expert Opinion on Biological Therapy

Volumn 13, Issue 9, 2013, Pages 1315-1323

  Kanellopoulou, Theoni ^a   Alexopoulou, Alexandra ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Angiogenesis inhibitor; Bevacizumab; Hereditary hemorrhagic telangiectasia; Systemic treatment; Topical treatment; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; THALIDOMIDE;

ABDOMINAL PAIN; ANGIOGENESIS; ARTERIOVENOUS MALFORMATION; ARTICLE; BLOOD TRANSFUSION; CONSTIPATION; CYTOPENIA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; LUNG HEMORRHAGE; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENDU OSLER WEBER DISEASE; SYSTEMIC THERAPY; URINARY TRACT INFECTION; VOMITING; WEAKNESS; WOUND HEALING IMPAIRMENT;

EID: 84881504805     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.813478     Document Type: Article

References (55)

1. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24: 203-19
2. Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000; 95(2): 415-18 (Pubitemid 30106169)
3. Cottin V, Plauchu H, Bayle JY, et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004; 169: 994-1000 (Pubitemid 38543636)
4. Verkerk MM, Shovlin CL, Lund VJ. Silent threat? A retrospective study of screening practices for pulmonary arteriovenous malformations in patients with hereditary haemorrhagic telangiectasia. Rhinology 2012; 50: 277-83
5. Buonamico P, Suppressa P, Lenato GM, et al. Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs multislice computed tomography study. J Hepatol 2008; 48: 811-20
6. Krings T, Ozanne A, Chng SM, et al. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology 2005; 47(10): 711-20 (Pubitemid 41554551)
7. Garcia-Tsao G, Korzenik JR, Young L, et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000; 343: 931-6
8. Dupuis-Girod S, Bailly S, Plauchu H. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost 2010; 8: 1447-56
9. McDonald J, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia. Haematologica 2005; 90: 728-32 (Pubitemid 40897213)
10. Shovlin CL, Jackson JE, Bamford KB, et al. Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 2008; 63: 259-66 (Pubitemid 351373723)
11. Shovlin C, Bamford K, Wray D. Post-NICE 2008: antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia. Br Dent J 2008; 205: 531-3
12. Lund VJ, Howard DJ. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol 1999; 13: 319-22
13. Hitchings AE, Lennox PA, Lund VJ, Howard DJ. The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol 2005; 19: 75-8 (Pubitemid 40444009)
14. Bergler W, Sadick H, Gotte K, et al. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol 2002; 111(3 Pt 1): 222-8 (Pubitemid 34233348)
15. Kühnel TS, Wagner BH, Schurr CP, Strutz J. Clinical strategy in hereditary hemorrhagic telangiectasia. Am J Rhinol 2005; 19: 508-13 (Pubitemid 41671820)
16. Faughnan ME, Palda VA, Garcia-Tsao G, et al. HHT Foundation International - Guidelines Working Group. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48: 73-87
17. Sadick H, Bergler WF, Oulmi-Kagermann J, et al. Estriol induced squamous metaplasia on the nasal mucosa in patients with hereditary hemorrhagic telangiectasia. Arch Med Res 2005; 36: 468-73 (Pubitemid 41140050)
18. Yaniv E, Preis M, Shevro J, et al. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial. Rhinology 2011; 49: 214-16
19. Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med 2001; 161: 767 (Pubitemid 32200234)
20. Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009; 17: 860-71
21. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-28
22. Giordano P, Lenato GM, Pierucci P, et al. Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia. J Pediatr Hematol Oncol 2009; 31: 577-82
23. Genetech. Avastin (bevacizumab) product insert. Available from: http://www.gene.com/download/pdf/avastin-prescribing.pdf
24. CATT Research Group. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908
25. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50 (Pubitemid 32119100)
26. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients. A metaanalysis. JAMA 2011; 305: 487-94
27. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360: 2143-4
28. Brinkerhoff BT, Poetker DM, Choong NW. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2010; 364: 688-9
29. Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 361: 931
30. Suppressa P, Liso A, Sabbà C. Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. Br J Haematol 2011; 152: 365
31. Fodstad P, Dheyauldeen S, Rinde M, Bachmann-Harildstad G. Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia. Ann Hematol 2011; 90: 611-12
32. Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006; 85: 631-2 (Pubitemid 44283088)
33. Mitchell A, Adams LA, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008; 14: 210-13 (Pubitemid 351267278)
34. Fleagle JM, Bobba RK, Kardinal CG, et al. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab. Am J Med Sci 2012; 343: 249-51
35. Amanzada A, Töppler GJ, Cameron S, et al. A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab. Case Rep Oncol 2010; 3: 463-70
36. Lazaraki G, Akriviadis E, Pilpilidis I, et al. Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2011; 106: 2204-6
37. Brinkerhoff BT, Choong NW, Treisman JS, et al. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia. Am J Otolaryngol 2012; 33: 349-51
38. Retornaz F, Rinaldi Y, Duvoux C. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 361: 931
39. Lupu A, Stefanescu C, Treton X, et al. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2013; 47: 256-7
40. Chavan A, Schumann-Binarsch S, Luthe L, et al. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). Vasa 2013; 42: 106-10
41. Vlachou PA, Colak E, Koculym A, et al. Improvement of ischemic cholangiopathy in three patients with hereditary hemorrhagic telangiectasia following treatment with bevacizumab. J Hepatol 2013; 59: 816-9
42. Cruikshank RP, Chern BW. Bevacizumab and hereditary haemorrhagic telangiectasia. Med J Aust 2011; 194: 324-5
43. Jamshidi N, Miller FJ, Mandel J, et al. Individualized therapy of HHT driven by network analysis of metabolomic profiles. BMC Syst Biol 2011; 5: 200
44. Föllner S, Ibe M, Schreiber J. Bevacizumab treatment in hereditary hemorrhagic teleangiectasia. Eur J Clin Pharmacol 2012; 68: 1685-6
45. Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012; 307: 948-55
46. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-7 (Pubitemid 350167096)
47. Dheyauldeen S, Østertun Geirdal A, Osnes T, et al. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose. Laryngoscope 2012; 122: 1210-14
48. Guldmann R, Dupret A, Nivoix Y, et al. Bevacizumab nasal spray: noninvasive treatment of epistaxis in patients with Rendu-Osler disease. Laryngoscope 2012; 122: 953-5
49. Karnezis TT, Davidson TM. Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121: 636-8
50. Karnezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope 2012; 122: 495-7
51. Simonds J, Miller F, Mandel J, et al. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119: 988-92
52. Rohrmeier C, Sachs HG, Kuehnel TS. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 2012; 269: 531-6
53. Chen S, Karnezis T, Davidson TM. Safety of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia- associated epistaxis. Laryngoscope 2011; 12: 644-6
54. Olitsky SE. Topical timolol for the treatment of epistaxis in hereditaryhemorrhagic telangiectasia. Am J Otolaryngol 2012; 33: 375-6
55. Kaja S, Hildenberg JD, Everett E, et al. Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies. Hum Antibodies 2011; 20: 95-101